Umpqua Bank Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Umpqua Bank raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,394 shares of the biopharmaceutical company’s stock after purchasing an additional 82 shares during the period. Umpqua Bank’s holdings in Regeneron Pharmaceuticals were worth $1,465,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of REGN. West Paces Advisors Inc. grew its position in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the period. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $26,000. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $28,000. Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Family Firm Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 1.7 %

Shares of Regeneron Pharmaceuticals stock opened at $1,131.50 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The company has a market capitalization of $124.68 billion, a PE ratio of 33.43, a P/E/G ratio of 3.13 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The business has a 50-day moving average of $1,113.10 and a 200-day moving average of $1,020.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the prior year, the business posted $8.79 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Michael S. Brown sold 1,535 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total value of $1,596,400.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,437,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Michael S. Brown sold 1,535 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $1,040.00, for a total value of $1,596,400.00. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,437,280. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Leonard S. Schleifer sold 9,064 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total value of $9,203,857.52. Following the completion of the sale, the chief executive officer now owns 55,134 shares of the company’s stock, valued at $55,984,717.62. The disclosure for this sale can be found here. Over the last quarter, insiders sold 20,625 shares of company stock valued at $22,298,963. 7.48% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $1,250.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday. Truist Financial reissued a “buy” rating and set a $1,200.00 price objective (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 2nd. Evercore ISI started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target for the company. Finally, Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,108.95.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.